Form 4: OnKure Director Acquires 15,300 Stock Options

OnKure Therapeutics Director Liam Ratcliffe acquired 15,300 stock options with an exercise price of $4.14, demonstrating continued alignment with shareholder interests.

Summary

• Liam Ratcliffe, a Director of OnKure Therapeutics, Inc. (OKUR), acquired 15,300 stock options.
• The transaction date for the option grant was March 31, 2026.
• Each option has an exercise price of $4.14.
• The options will vest over 36 months, with 1/36th of the shares vesting on April 30, 2026, and on the last day of each month thereafter.
• Vesting is contingent upon Mr. Ratcliffe continuing as a service provider to the company.
• The options have an expiration date of March 30, 2036.
• Following this transaction, Mr. Ratcliffe directly beneficially owns 15,300 derivative securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates a director's continued alignment with the company's long-term performance through equity incentives, though it's not a direct cash investment.

Positives

• The acquisition of stock options by a director indicates continued alignment of management's interests with those of shareholders.
• The long vesting schedule (36 months) incentivizes long-term commitment and performance from the director.

Negatives

• This is an option grant, not an outright purchase of shares, meaning the director has not yet invested personal capital directly into the company's stock.

Future Outlook

The vesting schedule for the stock options, extending over 36 months, implies an expectation of Liam Ratcliffe's continued service to OnKure Therapeutics, Inc. for the foreseeable future.

Industry Context

StockSavvy.ai notes that grants of stock options to directors are a common form of equity compensation, designed to align the interests of company leadership with long-term shareholder value creation. This type of insider activity is generally viewed as a positive signal, indicating confidence in the company's future prospects, although it differs from direct share purchases which involve immediate capital outlay.

Stakeholder Impact

• Shareholders: Potentially positive, as director's interests are further aligned with long-term stock performance.

Next Steps

• Continued service of Liam Ratcliffe to OnKure Therapeutics, Inc.
• Monthly vesting of stock options, commencing April 30, 2026.
• Potential exercise of options by Liam Ratcliffe before the expiration date of March 30, 2036.

Key Dates

Recommendation

A single Form 4 filing detailing a routine stock option grant to a director, while a positive signal of alignment, is generally not sufficient on its own to warrant a strong buy or sell recommendation. It provides a data point on insider incentives but does not offer comprehensive financial or operational insights to change an investment thesis.

Keywords

OnKure Therapeutics, OKUR, Liam Ratcliffe, Director, Stock Options, Insider Transaction, SEC Form 4, Equity Compensation, Vesting Schedule